Patient Safety After a Death: What Transparency Can and Cannot Do

Ibogaine clinic patient death reporting raises the question of what transparency can do for safety without violating privacy or creating premature certainty. The article references an Ambio public statement on a patient death reported on January 21, 2026, and argues that key facts often remain unconfirmed while families and privacy rules limit what can be disclosed. It warns that speculation can quickly harden into certainty before evidence exists, even when more communication is generally better than silence. It connects this tragedy to systemic gaps in the ibogaine ecosystem, including providers operating in isolation, inconsistent screening, and the lack of shared infrastructure for learning from near misses and adverse events. The piece argues that prohibition and legal risk discourage data sharing, and proposes a central safety mechanism such as a consortium, safety table, or protected adverse event reporting channel that allows protocol improvement while limiting liability through guardrails.